Infertility Drugs and Devices Market, By Type (Infertility Drugs (Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin), Infertility Devices (Equipment, Accessories)), By Gender (Male, Female), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) -

Published In : Jul 2023

Code : CMI4122

Pages :165

Formats :

Excel and PDF

Industry : Pharmaceutical

Market Challenges And Opportunities

Global Infertility Drugs and Devices Market– Drivers

Increasing prevalence of infertility

Increasing prevalence of infertility is expected to propel growth of the global infertility drugs and devices market over the forecast period. For instance, according to the National Survey of Family Growth data published in September 2022, reported 20.5% of all women intend to become pregnant are infertile and 9.7% of married women aged 15 to 44 years are infertile, in the U.S.

Increasing homosexual population

Increasing homosexual population is also expected to drive the market growth.For instance, in September 2021, Williams Institute at the UCLA School of Law reported that around 8.5% of the U.S. adults were identified as lesbian, gay, bisexual or transgender.

Global Infertility Drugs and Devices Market: Restraint

Presence of effective alternatives to medications

Presence of effective alternatives to medications and its increased adoption rate may have a negative impact on the market growth. According to a research article published in Reproductive Biomedicine, in November 2021, over 2.5 billion In vitro fertilization (IVF) procedures are performed annually worldwide. Most Europe countries provide complete funding for several IVF procedures. Hence, the threat of substitutes is expected to be high during the forecast period. However, the market has witnessed the patient shift towards medical procedures including ART and IVF in combination with infertility medications, which may support the market growth.